“The Company continues to achieve key milestones for our prospective ExoPTEN drug and the development of an exosome-based therapy platform to be potentially used to achieve functional recovery in acute injuries related to the central nervous system,” said Dr. Lior Shaltiel, CEO of NurExone. “We believe that the advancements made